Atea Pharmaceuticals
Utility Patents

Last updated:

List of all Atea Pharmaceuticals patents 10 in total

Status Patent
Grant
Utility: 2'-substituted-N6-substituted purine nucleotides for RNA virus treatment External link
Filling date: 26 Sep 2025 Issue date: 16 Mar 2021
Grant
Utility: Nucleotide hemi-sulfate salt for the treatment of hepatitis C virus External link
Filling date: 26 Sep 2025 Issue date: 2 Feb 2021
Grant
Utility: Nucleotide hemi-sulfate salt for the treatment of hepatitis C virus External link
Filling date: 26 Sep 2025 Issue date: 19 Jan 2021
Grant
Utility: Highly active compounds against COVID-19 External link
Filling date: 26 Sep 2025 Issue date: 29 Dec 2020
Grant
Utility: .beta.-d-2'-deoxy-2'-.alpha.-fluoro-2'-.beta.-c-substituted-2-modified-n.s- up.6-substituted purine nucleotides for HCV treatment External link
Filling date: 26 Sep 2025 Issue date: 29 Dec 2020
Grant
Utility: .beta.-D-2'-deoxy-2'-.alpha.-fluoro-2'-.beta.-C-substituted-2-modified-N.s- up.6-substituted purine nucleotides for HCV treatment External link
Filling date: 26 Sep 2025 Issue date: 22 Dec 2020
Grant
Utility: .beta.-D-2'-deoxy-2'-.alpha.-fluoro-2'-.beta.-C-substituted-2-modified-N6-- substituted purine nucleotides for HCV treatment External link
Filling date: 26 Sep 2025 Issue date: 22 Dec 2020
Grant
Utility: .beta.-D-2'-deoxy-2'-.alpha.-fluoro-2'-.beta.-C-substituted-2-modified-N.s- up.6-substituted purine nucleotides for HCV treatment External link
Filling date: 26 Sep 2025 Issue date: 27 Oct 2020
Grant
Utility: Beta-d-2'-deoxy-2'-alpha-fluoro-2'-beta-c-substituted-4'fluoro-n6-substitu- ted-6-amino-2-substituted purine nucleotides for the treatment of hepatitis c virus infection External link
Filling date: 26 Sep 2025 Issue date: 14 Jul 2020
Grant
Utility: Nucleotide hemi-sulfate salt for the treatment of hepatitis C virus External link
Filling date: 26 Sep 2025 Issue date: 31 Dec 2019

Showing 1 to 10 of 10 patents.